Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

[1]  Kihyun Kim,et al.  Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study) , 2022, Frontiers in Oncology.

[2]  G. Castellani,et al.  Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Rajkumar,et al.  Multiple myeloma: 2022 update on diagnosis, risk stratification, and management , 2022, American journal of hematology.

[4]  M. Vekemans,et al.  Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. , 2022, Blood.

[5]  M. Mateos,et al.  High-risk multiple myeloma: how to treat at diagnosis and relapse? , 2021, Hematology. American Society of Hematology. Education Program.

[6]  Junshik Hong,et al.  Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma , 2021, Therapeutic advances in hematology.

[7]  R. Orlowski,et al.  Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. , 2020, Blood advances.

[8]  S. Ševčíková,et al.  Extramedullary disease in multiple myeloma - controversies and future directions. , 2019, Blood reviews.

[9]  P. Thall,et al.  Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. , 2019, The Lancet. Haematology.

[10]  S. Parmar,et al.  High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. , 2017, The Lancet. Haematology.

[11]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[12]  B. Barlogie,et al.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial , 2017, The Lancet.

[13]  S. Raza,et al.  Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist , 2017, Therapeutic advances in hematology.

[14]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[15]  R. Vij,et al.  Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  S. Lonial,et al.  Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients , 2014, Leukemia.

[17]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[18]  M. Dimopoulos,et al.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. , 2011, Blood.

[19]  A. Chanan-Khan,et al.  Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Drabick,et al.  BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma , 2009, Bone Marrow Transplantation.

[21]  H. Brenner,et al.  Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.

[22]  J. Finke,et al.  Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period , 2006, Annals of Hematology.

[23]  J. Miguel,et al.  Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple Myeloma , 2002, Leukemia & lymphoma.

[24]  J. Miguel,et al.  Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma , 2000, British journal of haematology.

[25]  M. Cazzola,et al.  The possible role of burden of therapy on the risk of myeloma extramedullary spread , 2016, Annals of Hematology.

[26]  C. Solano,et al.  Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  B. Pégourié,et al.  Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). , 2010, Blood.

[28]  M. Martelli,et al.  Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. , 2004, The hematology journal : the official journal of the European Haematology Association.